TCR2 Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of TCR2 Therapeutics generated cash of -$101,461,000, which is less than the previous year. Cash used in financing activities reached the amount of $125,000 last year. Net change in cash is therefore -$189,822,000.
Cash Flow
| 2016 | -9.38M | -9.21M | 22.48M |
|---|---|---|---|
| 2017 | -12.03M | 7.67M | 16.18M |
| 2018 | -18.77M | -76.33M | 122.98M |
| 2019 | -41.35M | -20.41M | 79.52M |
| 2020 | -56.73M | -48.93M | 134.69M |
| 2021 | -81.60M | 78.44M | 132.13M |
| 2022 | -101.46M | -88.48M | 125K |
TCRR Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 223.72M | 94.73M | 65.71M | 47.96M | 19.81M | 7.99M | 4.10M |
Operating activities | |||||||
Net income | -151.82M | -99.80M | -67.12M | -47.59M | -24.25M | -13.07M | -9.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.04M | 2.82M | 1.59M | 862K | 419K | 298K | 220K |
Stock-based compensation expense | 11.38M | 12.26M | 8.49M | 6.70M | 2.13M | 408K | 93K |
| Deferred income tax benefit | 11.38M | 12.26M | 8.49M | 6.70M | 2.13M | 408K | 93K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.16M | -771K | 451K | -179K | 2.22M | -101K | 76K |
Cash generated by operating activities | -101.46M | -81.60M | -56.73M | -41.35M | -18.77M | -12.03M | -9.38M |
Investing activities | |||||||
Purchases Of Investments | -267.52M | -50.72M | -152.81M | -126.26M | -97.81M | -6.48M | -8.35M |
Investments In Property Plant And Equipment | -15.45M | -11.44M | -7.16M | -3.87M | -1.01M | -388K | -869K |
Acquisitions Net | 15.45M | 351K | 7.77M | 4.14M | 1.03M | 0 | 0 |
Cash generated by investing activities | -88.48M | 78.44M | -48.93M | -20.41M | -76.33M | 7.67M | -9.21M |
Financing activities | |||||||
Common Stock Issued | 256K | 131.33M | 133.57M | 79.13M | 125M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 125K | 132.13M | 134.69M | 79.52M | 122.98M | 16.18M | 22.48M |
Net Change In Cash | -189.82M | 128.98M | 29.02M | 17.74M | 27.86M | 11.81M | 3.88M |
Cash at end of period | 33.89M | 223.72M | 94.73M | 65.71M | 47.67M | 19.81M | 7.99M |
| Data source | Data source | Data source | Data source | Data source |